Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson's COVID-19 Vaccine Inventory Is Lighter Than Expected

By Cory Renauer - Feb 17, 2021 at 6:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If authorized for emergency use later this month, the White House expects just a few million doses of Johnson & Johnson's coronavirus vaccine candidate in its inventory by the end of February.

The White House COVID-19 Response Team held a briefing on Wednesday where Joe Biden's recently appointed COVID-19 response coordinator, Jeff Zients, told the public some news we weren't happy to hear. It looks like the U.S. government will only have a few million doses of Johnson & Johnson's (JNJ 0.91%) coronavirus vaccine candidate in inventory by the end of February.  

Zients said Johnson & Johnson still has a deal to supply the U.S. with 100 million doses of its vaccine candidate by the end of June. Unfortunately, the U.S. only expects a sliver of that commitment in its inventory by the time the FDA is expected to issue an authorization decision.  

Person working in a life science laboratory.

Image source: Getty Images.

Johnson & Johnson submitted a request for emergency use authorization (EUA) of its coronavirus vaccine candidate earlier this month. The FDA has scheduled a meeting of independent medical experts to publicly pick through all the data on Feb. 26. The agency is expected to issue an authorization decision shortly after the meeting.

Unlike currently authorized COVID-19 vaccines from Pfizer (PFE -0.15%) and Moderna (MRNA 8.73%), J&J's vaccine doesn't require a booster shot. During a phase 3 trial with more than 40,000 participants, J&J's vaccine was 66% effective at preventing moderate to severe COVID-19.

If authorized later this month J&J's vaccine candidate could accelerate a safe return to normal in time for the best summer ever. While J&J's vaccine candidate produced arguably less impressive clinical trial results than the competition, it's hardly a good reason to turn down a jab from J&J if given the opportunity. While it doesn't appear quite as effective at the prevention of symptomatic infection, it did demonstrate complete protection against COVID-19 related hospitalizations and deaths.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$181.09 (0.91%) $1.63
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.91 (-0.15%) $0.08
Moderna, Inc. Stock Quote
Moderna, Inc.
$147.66 (8.73%) $11.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.